Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
Singh
Saranjit
S
Mariappan
T T
TT
Bhutani
Hemant
H
D000904:Antibiotics, Antitubercular / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001682:Biological Availability; D004338:Drug Combinations; D006801:Humans; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D000904:Antibiotics, Antitubercular; D004338:Drug Combinations; D012293:Rifampin